Matchpoint Therapeutics Inc. and Novartis AG have entered into an exclusive option and license agreement to develop and commercialize oral covalent inhibitors targeting a transcription factor linked to a number of inflammatory diseases. Matchpoint’s approach leverages the properties of covalent chemistry and a proprietary platform to target a novel binding site on a historically hard-to-drug protein.
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
Serine/threonine-protein kinase NEK7 inhibitors are described in a recent Beijing Primegene Therapeutics Co. Ltd. patent. They are reported to be useful for the treatment of gout, osteoarthritis, amyotrophic lateral sclerosis, multiple sclerosis, ulcerative colitis, Alzheimer’s, Parkinson’s disease and cancer.
DCB-USA LLC and the Development Center for Biotechnology have patented heterocycle compounds acting as fMet-Leu-Phe receptor (fMLP; FPR1) antagonists reported to be useful for the treatment of cancer, acute respiratory distress syndrome, asthma, arthritis, chronic obstructive pulmonary disease, lung injury, ischemia-reperfusion injury and septicemia.
Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by chronic inflammation and structural damage to the alveoli, with irreversible declined lung function. M1 pro-inflammatory macrophages mainly participate in airway inflammation and in tissue destruction, and are involved in COPD, but the mechanisms need to be elucidated.
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China.
AC Immune SA has synthesized new heterocyclic modulators acting as NLRP3 inflammasome inhibitors. As such, they are reported to be potentially useful for the treatment of asthma, atherosclerosis, obesity, gout, cryopyrin-associated periodic syndromes, nonalcoholic fatty liver disease (NAFLD), Parkinson’s and Alzheimer’s disease, among others.
RSS
